Who Paid My Doc
Blincyto
Biological Oncology
NDC 55513-160-01
General payments
$3,710,023
Research payments
$397,696,905
Through program year 2025, $3,710,023 in general payments and $397,696,905 in research payments were reported against Blincyto (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $730,510 | 963 |
| 2025 | Research | $104,185,765 | 108 |
| 2024 | General | $579,686 | 886 |
| 2024 | Research | $9,851,496 | 103 |
| 2023 | General | $341,204 | 3,253 |
| 2023 | Research | $5,577,965 | 59 |
| 2022 | General | $329,114 | 2,273 |
| 2022 | Research | $52,876,381 | 62 |
| 2021 | General | $500,664 | 1,882 |
| 2021 | Research | $93,315,438 | 142 |
| 2020 | General | $507,586 | 856 |
| 2020 | Research | $80,690,955 | 138 |
| 2019 | General | $721,259 | 1,449 |
| 2019 | Research | $51,198,905 | 123 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 44 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 39 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
11,562 general · 735 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.